22 February, 2017
Trovagene, Inc. (NASDAQ: TROV), (San Diego, CA), a developer of circulating tumor DNA (ctDNA) technologies, signed a distribution agreement with AGBL (Dubai, UAE) to bring Trovagene Liquid Biopsy tests to AGBL’s markets.
“Trovagene has innovative liquid biopsy solutions for cancer patients,” said Dr. Simona Maciotta, Product Manager at AGBL. “Their clinically, actionable, highly sensitive mutation assays will allow clinicians to make critical decisions about medication and prognosis more quickly, which can have a life-changing impact on patients’ lives.”
Headquartered in San Diego, California, Trovagene is leveraging its proprietary Precision Cancer Monitoring® (PCM) technology in an effort to enable itself and others through the distribution of research use kits and systems, to detect and monitor ctDNA in urine and blood. The Company’s technology allows for detection and quantitation of oncogene mutations in cancer patients for improved disease management. Trovagene’s PCM technology is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property, including multiple issued patents and pending patent applications globally. For more information, please visit: https://www.trovagene.com/
AGBL is the largest biomedical gateway to the emerging markets of the Middle East, Africa and Asia. The group is dedicated to bringing innovative technologies and products to researchers, clinicians, and diagnostic users in the emerging healthcare markets within the MEAA region. The group’s stated mission is to improve the lives of the region’s inhabitants through novel biomedical technologies and products. For more information, please visit: www.agbl.net
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to future uses, quality or performance of, or benefits of using, products or technologies, the expected benefits of the agreement between AGBL and Trovagene and other future events.
AGBL undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.
Ms. Ishah Butt
© Press Release 2017
© Copyright Zawya. All Rights Reserved.